CRISPR Therapeutics (NASDAQ: CRSP) has hired Tony Ho to serve as the company’s executive vice president and head of research and development. Switzerland-based CRISPR Therapeutics, which maintains its R&D operations in Cambridge, MA, is developing therapies based on the CRISPR gene-editing technology. Ho comes to the company from AstraZeneca (NYSE: AZN), where he was senior vice president and head of oncology integration and innovation.
Sponsored · Webinar
Robust, sensitive, & easy-to-use cell-based, reporter gene assays to study signaling pathways
Eurofins DiscoverX
Sponsored · Whitepaper
Leveraging technology & expertise to ensure a continual journey from trials to treatments
PRA Health Sciences
Sponsored · Whitepaper
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research
Brex
